Literature DB >> 34988960

Greater occipital nerve block is an effective treatment method for primary headaches?

Buse Rahime Hasırcı Bayır1, Gizem Gürsoy2, Ceyhun Sayman1, Gülbün Asuman Yüksel1, Yılmaz Çetinkaya1.   

Abstract

OBJECTIVES: Headache is one of the most common health problems, and it severely reduces the quality of life. The present study examines the efficacy of greater occipital nerve (GON) block in patients monitored for primary headaches.
METHODS: The present study includes 53 patients monitored by the headache outpatient clinic from March 2017 to June 2018, evaluates them for headache type, attack duration, attack frequency, severity of pain, and analgesic intake and compares the initial values with the follow-up values at months 1, 3, and 6.
RESULTS: The study group comprises 36 episodic migraine cases, 12 tension-type headache (TTH) cases, 4 chronic migraine cases, and 1 cluster headache case. In migraine group, VAS scores, attack durations, and the mean value of monthly number of attacks and analgesics taken significantly decrease compared to initial values at the end of the 6-month follow-up period. In TTH group, VAS scores, attack durations, and the mean value of monthly number of attacks and analgesics taken significantly decrease compared to initial values at the end of the 3-month follow-up period. Since only 2 of 12 patients completed the 6-month follow-up, although there was a decrease in the 6-month data, it was found to be statistically insignificant.
CONCLUSION: Repetitive GON block is an effective treatment method for migraine and TTH.

Entities:  

Mesh:

Year:  2022        PMID: 34988960     DOI: 10.14744/agri.2021.32848

Source DB:  PubMed          Journal:  Agri        ISSN: 1300-0012


  1 in total

1.  Ultrasound-guided 5-in-1 trigger point injection for treating tension-type headache: A case report.

Authors:  Jun Young Kim; Yoo Jin Choo; Min Cheol Chang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.